* Spero Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on May 15 for the period ending March 31 2024
* The Cambridge Massachusetts-based company is expected to report a 940.8% increase in revenue to $21.533 million from $2.07 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Spero Therapeutics Inc is for a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 300.0% in the last three months.
* Wall Street's median 12-month price target for Spero Therapeutics Inc is $7.50, above its last closing price of $1.64.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.23 -0.10 0.96 Beat 1,060
Sep. 30 2023 -0.02 -0.03 0.04 Beat 233.3
Jun. 30 2023 -0.33 -0.34 -0.23 Beat 33
Mar. 31 2023 -0.33 -0.33 -0.25 Beat 25
Dec. 0.04 0.55 Beat 1,169.
31 2022 3
Sep. 30 2022 -0.31 -0.30 -0.33 Missed -8.8
Jun. 30 2022 -0.92 -0.93 -0.87 Beat 6.1
Mar. 31 2022 -0.86 -0.87 -1.01 Missed -16.2
This summary was machine generated May 13 at 20:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments